UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC  20549

 

FORM 8-K

 

Current Report Pursuant Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):  June 17, 2015

 

Trimedyne, Inc.

(Exact Name of Registrant as

Specified in its Charter)

 

Nevada   36-3094439

(State of Other Jurisdiction of

Incorporation or Organization)

  (IRS Employer Identification No.)
 
5 Holland, #223, Irvine CA 92618
(Address of Principal Executive Offices)
 

Registrant's Telephone Number, Including Area Code:

(949) 951-3800

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act
   
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act
   
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
   
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

 
 

 

Section 5 — Corporate Governance and Management

 

Item 5.02. Departure of Directors or Certain Officers; Appointment of Certain Officers

On June 17, 2015, Glenn D. Yeik, current President, COO and Director, notified Trimedyne, Inc, (“the “Company”) of his decision to resign from office of Chairman of the Board of Directors of the Company, effective immediately. This resignation was not a result of any disagreement with the Company, its management or the Company’s Board or any matter relating to the Company’s operations, policies or practices. He remains, President, COO and a Director of the Company.

Further, Marvin P. Loeb, Sc.D, current Chief Scientific Officer, was elected to the additional office of Chairman of the Board of Directors, effective immediately. Dr. Loeb was formerly the Chief Executive Officer and Chairman of the Board of the Company.

 

 

 

 

 

 

 

 

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

  Trimedyne, Inc.
   
Date: June 17, 2015 By /s/ Glenn D. Yeik
    Glenn D. Yeik
    Principal Executive Officer
     
     
Date: June 17, 2015 By /s/ Jeffrey S. Rudner
    Jeffrey S. Rudner
    Principal Accounting Officer
         

 

 

 

 

 

 

 

 

3